



US005859058A

# United States Patent [19]

[11] Patent Number: **5,859,058**

Zimmerman et al.

[45] Date of Patent: **Jan. 12, 1999**

[54] **NITRIC OXIDE SYNTHASE INHIBITORS FOR INHIBITING THE PRODUCTION OF AIRWAY MUCAS**

[75] Inventors: **Thomas Paul Zimmerman**, Raleigh;  
**Luis Molina**, Chapel Hill, both of N.C.

[73] Assignee: **Glaxo Wellcome Inc.**, Research Triangle Park, N.C.

[21] Appl. No.: **765,547**

[22] PCT Filed: **Jul. 13, 1995**

[86] PCT No.: **PCT/GB95/01657**

§ 371 Date: **Apr. 11, 1997**

§ 102(e) Date: **Apr. 11, 1997**

[87] PCT Pub. No.: **WO96/02245**

PCT Pub. Date: **Feb. 1, 1996**

### Related U.S. Application Data

[63] Continuation of PCT/GB95/01657, Jul. 13, 1995, which ia a continuation of Ser. No. 275,167, Jul. 14, 1994, abandoned.

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 31/195**

[52] **U.S. Cl.** ..... **514/565**

[58] **Field of Search** ..... 514/565

### [56] References Cited

#### U.S. PATENT DOCUMENTS

5,028,627 7/1991 Kilbourn et al. .  
5,317,040 5/1994 Goldman .  
5,358,969 10/1994 Williamson et al. .... 514/632

#### OTHER PUBLICATIONS

“Neural nitric oxide synthase is localized in extrinsic nerves regulating perireceptor processes in the chemosensory nasal mucosae of rats and humans”, J. Comp. Neurol., vol. 345, No. 1, pp. 125–138, Jul. 1, 1994.

“TNF–alpha stimulates mucin secretion and gene expression in airway epithelium in vitro”, Chest, vol., 107, No. 3, pp. 133S–135S, Mar. 3, 1995.

“Impairment of endothelium–dependent pulmonary artery relaxation in chronic obstructive lung disease”, N. Engl. J. Med., vol. 324, No. 22, pp. 1539–1547 (1991).

*Primary Examiner*—Raymond Henley, III

*Attorney, Agent, or Firm*—Lorie Ann Morgan

### [57] ABSTRACT

The use of an NO synthase inhibitor, for example L-NMMA, in inhibiting the production of airway mucus secretion, e.g., in cystic fibrosis, chronic bronchitis and emphysema, is disclosed.

**6 Claims, No Drawings**